List of Excipients in API denosumab
✉ Email this page to a colleague
Detailed excipient profiles for denosumab
Excipient focus: ACETATE ION
denosumab drug variants containing ACETATE ION
| Company | Ingredient | NDC |
|---|---|---|
| Fresenius Kabi USA LLC | denosumab | 65219-668 |
| Fresenius Kabi USA LLC | denosumab | 65219-672 |
| >Company | >Ingredient | >NDC |
denosumab drug variants not containing ACETATE ION
| Company | Ingredient | NDC |
|---|---|---|
| Amgen Inc | denosumab | 55513-710 |
| Amgen Inc | denosumab | 55513-730 |
| Sandoz Inc | denosumab | 61314-228 |
| Sandoz Inc | denosumab | 61314-240 |
| Samsung Bioepis Co Ltd | denosumab | 71202-012 |
| >Company | >Ingredient | >NDC |
Excipient focus: ACETIC ACID
denosumab drug variants containing ACETIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Sandoz Inc | denosumab | 61314-228 |
| Sandoz Inc | denosumab | 61314-240 |
| Organon LLC | denosumab | 78206-193 |
| Organon LLC | denosumab | 78206-195 |
| CELLTRION USA Inc | denosumab-bmwo | 72606-037 |
| >Company | >Ingredient | >NDC |
denosumab drug variants not containing ACETIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Amgen Inc | denosumab | 55513-710 |
| Amgen Inc | denosumab | 55513-730 |
| Fresenius Kabi USA LLC | denosumab | 65219-668 |
| Fresenius Kabi USA LLC | denosumab | 65219-672 |
| Samsung Bioepis Co Ltd | denosumab | 71202-012 |
| >Company | >Ingredient | >NDC |
Excipient focus: HISTIDINE
denosumab drug variants containing HISTIDINE
| Company | Ingredient | NDC |
|---|---|---|
| Samsung Bioepis Co Ltd | denosumab | 71202-012 |
| Cordavis Limited | denosumab | 83457-012 |
| >Company | >Ingredient | >NDC |
denosumab drug variants not containing HISTIDINE
| Company | Ingredient | NDC |
|---|---|---|
| Amgen Inc | denosumab | 55513-710 |
| Amgen Inc | denosumab | 55513-730 |
| Sandoz Inc | denosumab | 61314-228 |
| Sandoz Inc | denosumab | 61314-240 |
| Fresenius Kabi USA LLC | denosumab | 65219-668 |
| >Company | >Ingredient | >NDC |
Excipient focus: HISTIDINE HYDROCHLORIDE MONOHYDRATE
denosumab drug variants containing HISTIDINE HYDROCHLORIDE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Cordavis Limited | denosumab | 83457-012 |
| >Company | >Ingredient | >NDC |
denosumab drug variants not containing HISTIDINE HYDROCHLORIDE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Amgen Inc | denosumab | 55513-710 |
| Amgen Inc | denosumab | 55513-730 |
| Sandoz Inc | denosumab | 61314-228 |
| Sandoz Inc | denosumab | 61314-240 |
| Fresenius Kabi USA LLC | denosumab | 65219-668 |
| >Company | >Ingredient | >NDC |
Excipient focus: HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE
denosumab drug variants containing HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Samsung Bioepis Co Ltd | denosumab | 71202-012 |
| >Company | >Ingredient | >NDC |
denosumab drug variants not containing HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Amgen Inc | denosumab | 55513-710 |
| Amgen Inc | denosumab | 55513-730 |
| Sandoz Inc | denosumab | 61314-228 |
| Sandoz Inc | denosumab | 61314-240 |
| Fresenius Kabi USA LLC | denosumab | 65219-668 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROCHLORIC ACID
denosumab drug variants containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Sandoz Inc | denosumab | 61314-228 |
| Sandoz Inc | denosumab | 61314-240 |
| >Company | >Ingredient | >NDC |
denosumab drug variants not containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Amgen Inc | denosumab | 55513-710 |
| Amgen Inc | denosumab | 55513-730 |
| Fresenius Kabi USA LLC | denosumab | 65219-668 |
| Fresenius Kabi USA LLC | denosumab | 65219-672 |
| Samsung Bioepis Co Ltd | denosumab | 71202-012 |
| >Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 20
denosumab drug variants containing POLYSORBATE 20
| Company | Ingredient | NDC |
|---|---|---|
| Amgen Inc | denosumab | 55513-710 |
| Amgen Inc | denosumab | 55513-730 |
| Sandoz Inc | denosumab | 61314-228 |
| Sandoz Inc | denosumab | 61314-240 |
| Fresenius Kabi USA LLC | denosumab | 65219-668 |
| >Company | >Ingredient | >NDC |
denosumab drug variants not containing POLYSORBATE 20
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM ACETATE
denosumab drug variants containing SODIUM ACETATE
| Company | Ingredient | NDC |
|---|---|---|
| Amgen Inc | denosumab | 55513-710 |
| Amgen Inc | denosumab | 55513-730 |
| CELLTRION USA Inc | denosumab-bmwo | 72606-037 |
| CELLTRION USA Inc | denosumab-bmwo | 72606-038 |
| CELLTRION USA Inc | denosumab-bmwo | 72606-058 |
| >Company | >Ingredient | >NDC |
denosumab drug variants not containing SODIUM ACETATE
| Company | Ingredient | NDC |
|---|---|---|
| Sandoz Inc | denosumab | 61314-228 |
| Sandoz Inc | denosumab | 61314-240 |
| Fresenius Kabi USA LLC | denosumab | 65219-668 |
| Fresenius Kabi USA LLC | denosumab | 65219-672 |
| Samsung Bioepis Co Ltd | denosumab | 71202-012 |
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM HYDROXIDE
denosumab drug variants containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Amgen Inc | denosumab | 55513-710 |
| Amgen Inc | denosumab | 55513-730 |
| Sandoz Inc | denosumab | 61314-228 |
| Sandoz Inc | denosumab | 61314-240 |
| Fresenius Kabi USA LLC | denosumab | 65219-668 |
| >Company | >Ingredient | >NDC |
denosumab drug variants not containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Samsung Bioepis Co Ltd | denosumab | 71202-012 |
| Cordavis Limited | denosumab | 83457-012 |
| CELLTRION USA Inc | denosumab-bmwo | 72606-037 |
| CELLTRION USA Inc | denosumab-bmwo | 72606-038 |
| CELLTRION USA Inc | denosumab-bmwo | 72606-058 |
| >Company | >Ingredient | >NDC |
Excipient focus: SORBITOL
denosumab drug variants containing SORBITOL
| Company | Ingredient | NDC |
|---|---|---|
| Amgen Inc | denosumab | 55513-710 |
| Amgen Inc | denosumab | 55513-730 |
| Sandoz Inc | denosumab | 61314-228 |
| Sandoz Inc | denosumab | 61314-240 |
| Fresenius Kabi USA LLC | denosumab | 65219-668 |
| >Company | >Ingredient | >NDC |
denosumab drug variants not containing SORBITOL
| Company | Ingredient | NDC |
|---|---|---|
| Amneal Pharmaceuticals LLC | denosumab-mobz | 70121-2701 |
| >Company | >Ingredient | >NDC |
Excipient focus: SORBITOL SOLUTION
denosumab drug variants containing SORBITOL SOLUTION
| Company | Ingredient | NDC |
|---|---|---|
| Amneal Pharmaceuticals LLC | denosumab-mobz | 70121-2701 |
| >Company | >Ingredient | >NDC |
denosumab drug variants not containing SORBITOL SOLUTION
| Company | Ingredient | NDC |
|---|---|---|
| Amgen Inc | denosumab | 55513-710 |
| Amgen Inc | denosumab | 55513-730 |
| Sandoz Inc | denosumab | 61314-228 |
| Sandoz Inc | denosumab | 61314-240 |
| Fresenius Kabi USA LLC | denosumab | 65219-668 |
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
denosumab drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Amgen Inc | denosumab | 55513-710 |
| Amgen Inc | denosumab | 55513-730 |
| Sandoz Inc | denosumab | 61314-228 |
| Sandoz Inc | denosumab | 61314-240 |
| Fresenius Kabi USA LLC | denosumab | 65219-668 |
| >Company | >Ingredient | >NDC |
denosumab drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Organon LLC | denosumab | 78206-193 |
| Organon LLC | denosumab | 78206-195 |
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
